MedTrace Logo

Genetic Testing for All Breast Cancer Patients (GET FACTS)

NCT04245176 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-05-04

No results posted yet for this study

Summary

This study is designed to determine the impact of a novel genetic counseling method on surgical decisions in individuals with newly diagnosed breast cancer

This research study involves an expedited and surgery-specific form of genetic counseling.

The names of the study methods involved in this trial are/is:

* Quantitative genetic counseling (discussion is guided by tables and graphs)
* Standard genetic counseling

Conditions

Interventions

BEHAVIORAL

Standard Genetic Counseling

Standard genetic counseling: Standard of care discussion

BEHAVIORAL

Quantitative Genetic Counseling

Quantitative genetic counseling: Discussion is guided by tables and graphs.

Sponsors & Collaborators

  • Myriad Genetics, Inc.

    collaborator INDUSTRY

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Tara King, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2025-12-01
Completion
2026-01-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04245176 on ClinicalTrials.gov